Buy 5 or more, save 35% · code · free shipping
ShopPeptides
Each vial ships with QR-verifiable Certificates of Analysis, tri-agonist sequence verification, and validated stability reports. Fulfilled from our Chicago cold chain with calibrated thermal monitoring.
1 × $299.00 = $299.00
4 more units of anything - mix and match - unlocks 35% off with code EHAB35.
Retatrutide 10 mg
$299.00
The certificate of analysis for the current lot (Lot R2025-10A) is sent on request, so you can review identity and purity testing before you order.
Request the lot COAResearch summary
Retatrutide is an investigational once-weekly peptide developed by Eli Lilly that activates three hormone receptors - GIP, GLP-1 and glucagon. It is the most clinically advanced 'triple agonist' studied for obesity and type 2 diabetes.
GIP and GLP-1 receptor activation are the 'incretin' signals behind drugs like tirzepatide and semaglutide (appetite, insulin secretion). Retatrutide adds glucagon receptor activation, which in research models is linked to higher energy expenditure and liver fat reduction.
2,339 adults with obesity and without diabetes, 80 weeks. Mean body-weight change was −17.6%, −23.7% and −25.0% across the three retatrutide arms versus −3.9% with placebo. In subgroups, knee osteoarthritis pain scores and sleep-apnea events per hour fell more than with placebo. Gastrointestinal effects were the most common adverse events.[1][5]
1,152 adults with obesity and type 2 diabetes, 80 weeks. Weight change was −11.9% to −18.8% versus −5.1% with placebo. Diarrhoea and nausea were more common than with placebo; hypotension and dysesthesia were also more frequent, and stopping treatment because of adverse events was more common at the two higher doses.[2]
537 adults with type 2 diabetes managed by diet and exercise, 40 weeks. HbA1c fell by 1.69 to 1.94 percentage points versus 0.81 with placebo, and body weight by 11.5% to 15.3% versus 2.6%.[3]
338 adults with obesity, 48 weeks. Weight change reached −24.2% in the highest-dose group versus −2.1% with placebo. Gastrointestinal events were dose-related, and heart rate rose in a dose-dependent way.[4]
Reviewed 2026-10-02. Summaries describe published research and regulatory records; they are not medical advice and do not describe how to use this product. Sold for laboratory research use only.